Estimated Revenue & Valuation
- CoreRx's estimated annual revenue is currently $45M per year.
- CoreRx's estimated revenue per employee is $201,000
- CoreRx has 224 Employees.
- CoreRx grew their employee count by 21% last year.
What Is CoreRx?
CoreRx® a CDMO with a focus on early phase drug product development, offering state of the art facilities to support your supply chain needs throughout the entire clinical trial process. Our integrated offerings provide comprehensive services for the development, manufacturing and testing of solid, liquid and semi-solid dosage forms. The art of drug product development is the core of what we do. We differentiate ourselves by mixing highly experienced scientists with a wide range of technologies to deliver optimal solutions to meet our clients needs. From simple formulations to complex, delayed or targeted release dosage forms, CoreRx's solutions maximize client investments, shorten development time and reduce overall costs. At CoreRx, you bring us your formulation challenge and we will supply the right ingredients to ensure your product reaches its maximum potential.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
NovaQuest Private Equity acquired CoreRx, Inc., a Clearwater, FL-based global contract development and manufacturing organization. The amount of the deal was not disclosed. Goldman Sachs Specialty Lending Group provided debt financing for the transaction. Affiliates of Signet Healthcare Partner ...
Robert Berg, CFO of CoreRx Pharma, with his family. From left to right, his children, Brendan, Hayley and Chelsea, son-in-law Andy, Robert ...
Additionally, Aimmune has entered into a commercial supply agreement with CoreRx, Inc., the Company's long-standing manufacturer of ...
CLEARWATER, Fla., June 7, 2017 /PRNewswire/ -- Today, CoreRx and Aimmune Therapeutics announced their expansion of Myerlake-3.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|